ANI Pharmaceuticals
ANIP
117 hedge funds and large institutions have $239M invested in ANI Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 27 increasing their positions, 48 reducing their positions, and 12 closing their positions.
25% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 12
1% more funds holding
Funds holding: 116 → 117 (+1)
0.44% more ownership
Funds ownership: 56.66% → 57.11% (+0.44%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less capital invested
Capital invested by funds: $253M → $239M (-$13.9M)
44% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 48
45% less call options, than puts
Call options by funds: $560K | Put options by funds: $1.01M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair Investment Management
Chicago,
Illinois
|
+$11.6M |
| 2 |
FWSM
First Wilshire Securities Management
Pasadena,
California
|
+$2.94M |
| 3 |
MCM
Marathon Capital Management
Hunt Valley,
Maryland
|
+$2.31M |
| 4 |
TSW
Thompson Siegel & Walmsley
Richmond,
Virginia
|
+$2.18M |
| 5 |
GACM
Global Alpha Capital Management
Montreal,
Quebec, Canada
|
+$2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$1.9M |
| 2 |
Goldman Sachs
New York
|
-$1.57M |
| 3 |
Charles Schwab
San Francisco,
California
|
-$1.39M |
| 4 |
CIC
Cornercap Investment Counsel
Atlanta,
Georgia
|
-$1.29M |
| 5 |
HSA
Hussman Strategic Advisors
Ellicott City,
Maryland
|
-$1.07M |
ANIP Hedge Fund Activity: Q3 2021 in Review
117 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q3 2021, worth a combined $239M — down 5.5% from $253M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ANIP positions and 12 closed out — a net gain of 3 holders — while 27 added to existing stakes and 48 trimmed.
The largest buyer was William Blair Investment Management, adding an estimated $11.6M. The largest seller was Dimensional Fund Advisors, cutting an estimated $1.9M.
- 117 institutional investors held ANI Pharmaceuticals (ANIP) as of Q3 2021, up from 116 in Q2 2021.
- Funds reported $239M of ANI Pharmaceuticals stock for Q3 2021, down 5.5% quarter-over-quarter.
- 15 funds opened new ANI Pharmaceuticals positions in Q3 2021 and 12 closed out, a net change of +3 holders.
- The largest ANI Pharmaceuticals buyer in Q3 2021 was William Blair Investment Management, an estimated $11.6M added.
- The largest ANI Pharmaceuticals seller in Q3 2021 was Dimensional Fund Advisors, an estimated $1.9M sold.
Based on aggregated 13F filings for Q3 2021.